DK2563362T3 - Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet - Google Patents

Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet

Info

Publication number
DK2563362T3
DK2563362T3 DK11719421.7T DK11719421T DK2563362T3 DK 2563362 T3 DK2563362 T3 DK 2563362T3 DK 11719421 T DK11719421 T DK 11719421T DK 2563362 T3 DK2563362 T3 DK 2563362T3
Authority
DK
Denmark
Prior art keywords
analogues
antiproliferative activity
exhibiting anticancer
dicarboxamides
cyclopropyl
Prior art date
Application number
DK11719421.7T
Other languages
Danish (da)
English (en)
Inventor
Daniel L Flynn
Michael D Kaufman
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Application granted granted Critical
Publication of DK2563362T3 publication Critical patent/DK2563362T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11719421.7T 2010-04-29 2011-04-29 Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet DK2563362T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32954810P 2010-04-29 2010-04-29
PCT/US2011/034556 WO2011137342A1 (en) 2010-04-29 2011-04-29 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites

Publications (1)

Publication Number Publication Date
DK2563362T3 true DK2563362T3 (da) 2014-06-23

Family

ID=44260801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11719421.7T DK2563362T3 (da) 2010-04-29 2011-04-29 Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet

Country Status (17)

Country Link
US (5) US20120058985A1 (enExample)
EP (1) EP2563362B1 (enExample)
JP (1) JP5795630B2 (enExample)
KR (1) KR20130109943A (enExample)
CN (1) CN103068384B (enExample)
AU (1) AU2011245248B2 (enExample)
BR (1) BR112012027743A2 (enExample)
CA (1) CA2800569A1 (enExample)
DK (1) DK2563362T3 (enExample)
ES (1) ES2475741T3 (enExample)
IL (1) IL222728A0 (enExample)
MX (1) MX2012012571A (enExample)
PH (1) PH12012502142A1 (enExample)
PT (1) PT2563362E (enExample)
RU (1) RU2012151012A (enExample)
SG (2) SG10201503394PA (enExample)
WO (1) WO2011137342A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
KR20130109943A (ko) * 2010-04-29 2013-10-08 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체
CN102702120A (zh) * 2012-04-06 2012-10-03 浙江工业大学 一种新化合物邻羟基苯基四嗪二甲酰胺及制备和应用
CN102702121B (zh) * 2012-04-06 2016-04-13 浙江工业大学 一种化合物间羟基苯基四嗪二甲酰胺及制备和应用
CA2871681A1 (en) 2012-05-08 2013-11-14 Derk Hogenkamp Alpha 7 nicotinic acetylcholine allosteric modulators, their derivatives and uses thereof
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP3327144B1 (en) 2013-02-25 2020-03-25 Novartis AG Novel androgen receptor mutation
US9193719B2 (en) * 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
CA2971874A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of trk kinase mediated tumor growth and disease progression
US20170079966A1 (en) * 2014-10-14 2017-03-23 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
BR112018068681A2 (pt) 2016-03-16 2019-01-15 Bayer Cropscience Ag derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas
CN106349158B (zh) * 2016-08-03 2020-02-28 杭州市西溪医院 一种c-Met小分子抑制剂、含其的药物组合物及其药学应用
CN107793363B (zh) * 2016-09-06 2021-02-26 上海医药工业研究院 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
CN106831707B (zh) * 2016-12-28 2019-09-20 杭州市西溪医院 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
CN109988108B (zh) * 2017-12-29 2022-04-29 江苏豪森药业集团有限公司 一种卡博替尼的制备方法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
CA3124112A1 (en) 2018-12-28 2020-07-02 Deciphera Pharmaceuticals, Llc Csf1r inhibitors for use in treating cancer
US11530206B2 (en) 2019-05-10 2022-12-20 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PT3966206T (pt) 2019-05-10 2023-11-10 Deciphera Pharmaceuticals Llc Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmos
JP7626722B2 (ja) 2019-06-17 2025-02-04 デシフェラ・ファーマシューティカルズ，エルエルシー アミノピリミジンアミドオートファジー阻害剤およびその使用方法
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
TW202337455A (zh) 2021-12-09 2023-10-01 美商迪賽孚爾製藥有限公司 Ｒａｆ激酶抑制劑及其使用方法
CN114394940B (zh) * 2022-01-26 2024-01-16 武汉工程大学 一种环丙基-1,1二酰胺类化合物及其制备方法和应用
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2025122952A1 (en) 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906167A (zh) * 2004-02-27 2007-01-31 卫材株式会社 新型吡啶衍生物及嘧啶衍生物(2)
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
BRPI0616799B8 (pt) 2005-08-24 2021-05-25 Eisai R&D Man Co Ltd derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
TW200806675A (en) 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
KR101380444B1 (ko) 2006-08-23 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 페녹시피리딘 유도체의 염 또는 그 결정 및 이들의 제조 방법
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
JPWO2008102870A1 (ja) 2007-02-23 2010-05-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆｒ遺伝子増幅細胞株に優れた細胞増殖阻害効果および抗腫瘍効果を示すピリジン誘導体またはピリミジン誘導体
US20110130406A1 (en) 2007-09-06 2011-06-02 Array Biopharma Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
JP2009203226A (ja) * 2008-01-31 2009-09-10 Eisai R & D Management Co Ltd ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
EP2248810A4 (en) 2008-02-18 2011-05-25 Eisai R&D Man Co Ltd METHOD FOR PRODUCING A PHENOXYPYRIDINE DERIVATIVE
AR075084A1 (es) * 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
WO2010064300A1 (ja) 2008-12-02 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食道癌治療用組成物
JP2010178651A (ja) 2009-02-04 2010-08-19 Eisai R & D Management Co Ltd Ｈｇｆｒ阻害物質の作用検定方法
KR20130109943A (ko) * 2010-04-29 2013-10-08 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체

Also Published As

Publication number Publication date
SG185073A1 (en) 2012-12-28
HK1184392A1 (zh) 2014-01-24
JP2013525458A (ja) 2013-06-20
CA2800569A1 (en) 2011-11-03
US20120252849A1 (en) 2012-10-04
PH12012502142A1 (en) 2017-04-21
KR20130109943A (ko) 2013-10-08
PT2563362E (pt) 2014-07-11
JP5795630B2 (ja) 2015-10-14
US20140194405A1 (en) 2014-07-10
EP2563362B1 (en) 2014-03-12
ES2475741T3 (es) 2014-07-11
IL222728A0 (en) 2012-12-31
CN103068384A (zh) 2013-04-24
WO2011137342A1 (en) 2011-11-03
US8637672B2 (en) 2014-01-28
AU2011245248A1 (en) 2012-12-20
US20120322834A1 (en) 2012-12-20
MX2012012571A (es) 2013-04-05
EP2563362A1 (en) 2013-03-06
SG10201503394PA (en) 2015-06-29
AU2011245248B2 (en) 2016-01-07
US20120058985A1 (en) 2012-03-08
US20150218130A1 (en) 2015-08-06
CN103068384B (zh) 2015-03-11
BR112012027743A2 (pt) 2017-03-14
RU2012151012A (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
DK2563362T3 (da) Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet
DK2640197T3 (da) Sammensætninger omfattende rebaudiosid a, rebaudiosid b og rebaudiosid d
BR112015002738A2 (pt) composto , e , composição farmacêutica
CL2014002899A1 (es) Composiciones pesticidas y procesos relacionados con ellas
EP2968286A4 (en) 2-AMINOPYRIMIDIN-6-ONE AND ANALOGUE WITH ANTIBODY AND ANTIPROLIFERATIVE EFFECT
GB201421740D0 (en) Noble metal-molecular sieve catalysts
DK2841429T3 (da) Tetrazolinonforbindelser og anvendelse deraf som pesticider
DK3660033T3 (da) Langtidsvirkende compstatinanaloger og tilhørende sammensætninger og fremgangsmåder
DK2822704T3 (da) Gas-bibeholdende overfladeafdækning, indretning og anvendelse
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
EP2814501A4 (en) MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
BR112014027730A2 (pt) material, e material não tecido
BR112018005754A2 (pt) benzamidas substituídas por isoxazolina e análogos como inseticidas.
EP2911160A4 (en) ELECTRICALLY CONDUCTIVE PASTE
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK2895163T3 (da) Sammensætninger der omfatter peg og ascorbat
DK2819974T3 (da) Gødningsmiddel, anvendelse deraf og fremstillingsfremgangsmåde
FR2969640B1 (fr) Poudre ignifuge, fongicide et parasiticide
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2807160T3 (da) Antifibrotiske forbindelser og anvendelser deraf
HRP20190529T1 (hr) Kombinirana bačva od nehrđajućeg čelika i drva
DK2914111T3 (da) Sammensætning omfattende chitosan og et fungicid
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
BR112016011430A2 (pt) agentes anticâncer e preparação dos mesmos.